Which has better valuation & earnings, MPLT or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$1.87 N/A

Is MPLT or RCKT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Rocket Pharmaceuticals N/A -69.61% -58.63%

Does the media favor MPLT or RCKT?

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Maplight Therapeutics. MarketBeat recorded 2 mentions for Rocket Pharmaceuticals and 1 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.60 beat Rocket Pharmaceuticals' score of 0.45 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is INBX or RCKT more profitable?

Rocket Pharmaceuticals' return on equity of -69.61% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -72.32% Rocket Pharmaceuticals N/A -69.61% -58.63%

Which has better earnings & valuation, AVLN or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A -$21.83 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$1.87 N/A

Is AVLN or RCKT more profitable?

Avalyn Pharma's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Rocket Pharmaceuticals N/A -69.61% -58.63%

Does the media prefer ARDX or RCKT?

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Ardelyx. MarketBeat recorded 2 mentions for Rocket Pharmaceuticals and 1 mentions for Ardelyx. Rocket Pharmaceuticals' average media sentiment score of 0.45 beat Ardelyx's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to XERS or RCKT?

In the previous week, Xeris Biopharma had 8 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 10 mentions for Xeris Biopharma and 2 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.45 beat Xeris Biopharma's score of -0.14 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Rocket Pharmaceuticals (RCKT) Competitors

$3.84 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.76 -0.08 (-2.08%)

As of 07/2/2026 07:37 PM Eastern

Compare

RCKT vs. MPLT, INBX, AVLN, ARDX, and XERS

Should you buy Rocket Pharmaceuticals stock or one of its competitors? MarketBeat compares Rocket Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rocket Pharmaceuticals include Maplight Therapeutics (MPLT), Inhibrx Biosciences (INBX), Avalyn Pharma (AVLN), Ardelyx (ARDX), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.

How does Rocket Pharmaceuticals compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Maplight Therapeutics presently has a consensus price target of $38.80, suggesting a potential upside of 4.61%. Rocket Pharmaceuticals has a consensus price target of $8.88, suggesting a potential upside of 131.12%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	3.07
Rocket Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33

Maplight Therapeutics' return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Maplight Therapeutics. MarketBeat recorded 2 mentions for Rocket Pharmaceuticals and 1 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.60 beat Rocket Pharmaceuticals' score of 0.45 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Maplight Therapeutics beats Rocket Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Rocket Pharmaceuticals' return on equity of -69.61% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Inhibrx Biosciences has higher revenue and earnings than Rocket Pharmaceuticals. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,101.15	-$140.05M	-$8.39	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

In the previous week, Rocket Pharmaceuticals had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 2 mentions for Rocket Pharmaceuticals and 0 mentions for Inhibrx Biosciences. Rocket Pharmaceuticals' average media sentiment score of 0.45 beat Inhibrx Biosciences' score of -0.35 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibrx Biosciences	Neutral
Rocket Pharmaceuticals	Neutral

Inhibrx Biosciences currently has a consensus target price of $150.00, suggesting a potential upside of 53.72%. Rocket Pharmaceuticals has a consensus target price of $8.88, suggesting a potential upside of 131.12%. Given Rocket Pharmaceuticals' higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Rocket Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33

Inhibrx Biosciences has a beta of 3.41, meaning that its stock price is 241% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

Summary

Rocket Pharmaceuticals beats Inhibrx Biosciences on 10 of the 13 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

In the previous week, Rocket Pharmaceuticals had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 2 mentions for Rocket Pharmaceuticals and 0 mentions for Avalyn Pharma. Rocket Pharmaceuticals' average media sentiment score of 0.45 beat Avalyn Pharma's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalyn Pharma	Neutral
Rocket Pharmaceuticals	Neutral

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Avalyn Pharma presently has a consensus price target of $59.00, indicating a potential upside of 98.45%. Rocket Pharmaceuticals has a consensus price target of $8.88, indicating a potential upside of 131.12%. Given Rocket Pharmaceuticals' higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Rocket Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33

Avalyn Pharma's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

Summary

Rocket Pharmaceuticals beats Avalyn Pharma on 7 of the 12 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Ardelyx currently has a consensus target price of $15.73, indicating a potential upside of 198.43%. Rocket Pharmaceuticals has a consensus target price of $8.88, indicating a potential upside of 131.12%. Given Ardelyx's stronger consensus rating and higher probable upside, equities analysts clearly believe Ardelyx is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Rocket Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33

Rocket Pharmaceuticals has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

Ardelyx has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 5.3% of Ardelyx shares are held by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ardelyx has higher revenue and earnings than Rocket Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$427.68M	3.04	-$61.60M	-$0.23	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Ardelyx. MarketBeat recorded 2 mentions for Rocket Pharmaceuticals and 1 mentions for Ardelyx. Rocket Pharmaceuticals' average media sentiment score of 0.45 beat Ardelyx's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ardelyx beats Rocket Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Xeris Biopharma has a net margin of 3.81% compared to Rocket Pharmaceuticals' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Xeris Biopharma had 8 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 10 mentions for Xeris Biopharma and 2 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.45 beat Xeris Biopharma's score of -0.14 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xeris Biopharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Xeris Biopharma has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.90	$550K	$0.06	138.00
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

Xeris Biopharma presently has a consensus target price of $10.80, indicating a potential upside of 30.43%. Rocket Pharmaceuticals has a consensus target price of $8.88, indicating a potential upside of 131.12%. Given Rocket Pharmaceuticals' higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Rocket Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Xeris Biopharma beats Rocket Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCKT vs. The Competition

Export

Metric	Rocket Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$419.30M	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.66%	6.50%
P/E Ratio	-2.05	21.61	28.02	24.70
Price / Sales	N/A	325.90	532.59	97.92
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	1.50	8.66	10.96	6.46
Net Income	-$223.12M	$23.81M	$3.57B	$337.01M
7 Day Performance	18.15%	3.39%	2.12%	1.69%
1 Month Performance	39.64%	10.81%	5.25%	3.81%
1 Year Performance	32.60%	62.61%	33.29%	23.90%

Rocket Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCKT Rocket Pharmaceuticals	2.2778 of 5 stars	$3.84 flat	$8.88 +131.1%	+32.6%	$419.31M	N/A	N/A	240	News Coverage Gap Down
MPLT Maplight Therapeutics	2.0573 of 5 stars	$34.30 +3.1%	$38.80 +13.1%	N/A	$1.42B	N/A	N/A	109
INBX Inhibrx Biosciences	2.2128 of 5 stars	$95.50 +0.7%	$150.00 +57.1%	+499.2%	$1.39B	$1.30M	N/A	166
AVLN Avalyn Pharma	3.6127 of 5 stars	$31.00 +0.9%	$59.00 +90.3%	N/A	$1.37B	N/A	N/A	51
ARDX Ardelyx	2.1596 of 5 stars	$5.23 -5.8%	$15.73 +200.7%	+22.7%	$1.37B	$407.32M	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCKT) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. MPLT, INBX, AVLN, ARDX, and XERS

How does Rocket Pharmaceuticals compare to Maplight Therapeutics?

Summary

How does Rocket Pharmaceuticals compare to Inhibrx Biosciences?

Summary

How does Rocket Pharmaceuticals compare to Avalyn Pharma?

Summary

How does Rocket Pharmaceuticals compare to Ardelyx?

Summary

How does Rocket Pharmaceuticals compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. MPLT, INBX, AVLN, ARDX, and XERS

How does Rocket Pharmaceuticals compare to Maplight Therapeutics?

Do analysts recommend MPLT or RCKT?

Is MPLT or RCKT more profitable?

Which has better valuation & earnings, MPLT or RCKT?

Do institutionals & insiders hold more shares of MPLT or RCKT?

Does the media favor MPLT or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Inhibrx Biosciences?

Is INBX or RCKT more profitable?

Do institutionals and insiders hold more shares of INBX or RCKT?

Which has better earnings & valuation, INBX or RCKT?

Does the media prefer INBX or RCKT?

Do analysts rate INBX or RCKT?

Which has more risk & volatility, INBX or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Avalyn Pharma?

Does the media favor AVLN or RCKT?

Do insiders and institutionals believe in AVLN or RCKT?

Do analysts prefer AVLN or RCKT?

Is AVLN or RCKT more profitable?

Which has better earnings & valuation, AVLN or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Ardelyx?

Do analysts prefer ARDX or RCKT?

Is ARDX or RCKT more profitable?

Which has more volatility & risk, ARDX or RCKT?

Do institutionals & insiders believe in ARDX or RCKT?

Which has higher valuation & earnings, ARDX or RCKT?

Does the media prefer ARDX or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Xeris Biopharma?

Is XERS or RCKT more profitable?

Do institutionals & insiders believe in XERS or RCKT?

Does the media refer more to XERS or RCKT?

Which has more risk and volatility, XERS or RCKT?

Which has stronger valuation & earnings, XERS or RCKT?

Do analysts recommend XERS or RCKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools